Výsledky vyhledávání - "S. N. Esatoglu"

AB1305 A SYSTEMATIC REVIEW OF AA AMYLOIDOSIS AMONG PATIENTS WITH BEHÇET’S SYNDROME

Autor: G. Karatemiz, S. N. Esatoglu, M. Gurcan, Y. Ozguler, S. Yurdakul, V. Hamuryudan, I. Fresko, M. Melikoglu, E. Seyahi, S. Ugurlu, H. Ozdogan, H. Yazici, G. Hatemi

Publikováno v: Annals of the Rheumatic Diseases. 81:1758.2-1759

BackgroundData on patients with Behçet’s syndrome (BS) complicated with AA amyloidosis is limited to case reports or case series with a small number of patients.ObjectivesIn this study, we aimed to perform a systematic review (SR) of published rep

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::deee280b59cdc5a24ae05800b96ec8c5
https://doi.org/10.1136/annrheumdis-2022-eular.3716

Zobrazit plný text záznamu

POS0816 DRUG SURVIVAL OF INFLIXIMAB IN BEHÇET’S SYNDROME PATIENTS WITH DIFFERENT TYPES OF INVOLVEMENT

Autor: S. N. Esatoglu, B. Tukek, S. S. Taflan, Y. Ozyazgan, D. Ucar, V. Hamuryudan, Y. Ozguler, E. Seyahi, M. Melikoglu, U. Uygunoglu, A. Siva, Z. Kutlubay, I. Fresko, S. Yurdakul, H. Yazici, G. Hatemi

Publikováno v: Annals of the Rheumatic Diseases. 81:697.2-698

BackgroundInfliximab (IFX) is an effective therapeutic option in the management of severe and refractory manifestations of Behçet’s syndrome (BS).ObjectivesWe aimed to evaluate long term drug survival of IFX in a large cohort of BS patients.Method

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ea4007c3961b6cf075baf3e612954184
https://doi.org/10.1136/annrheumdis-2022-eular.3951

Zobrazit plný text záznamu

POS0814 OUTCOME OF VASCULAR INVOLVEMENT OF BEHÇET’S SYNDROME TREATED WITH INFLIXIMAB: A RETROSPECTIVE COHORT STUDY

Autor: G. Hatemi, B. Tukek, S. N. Esatoglu, Y. Ozguler, S. S. Taflan, M. Melikoglu, S. Ugurlu, I. Fresko, Z. Kutlubay, S. Yurdakul, H. Yazici, V. Hamuryudan

Publikováno v: Annals of the Rheumatic Diseases. 81:696.2-697

BackgroundVascular involvement is the most common cause of mortality and an important cause of disability in patients with Behçet’s syndrome (BS). Cyclophosphamide has been the treatment choice for severe vascular involvement, but high frequency o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::44f385ea29f9db4880eeb7d2fa9f6299
https://doi.org/10.1136/annrheumdis-2022-eular.3836

Zobrazit plný text záznamu

AB0634 Variability in Phenotype Clusters in Behçet’s Syndrome: A Systematic Review

Autor: B. Macit, K. Akyuz, S. N. Esatoglu, G. Hatemi

Publikováno v: Annals of the Rheumatic Diseases. 81:1444.1-1444

BackgroundThe presence of distinct clinical phenotypes with clustering of certain organ manifestations is well-recognized Behçet’s syndrome (BS). Differences in demographic features, treatment response, and possibly inflammatory pathways involved

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a30daad6f1880be6c8745056afc3f794
https://doi.org/10.1136/annrheumdis-2022-eular.3907

Zobrazit plný text záznamu

AB1308 MYCOPHENOLATE FOR THE TREATMENT OF EYE INVOLVEMENT IN PATIENTS WITH BEHÇET’S SYNDROME

Autor: D. Ucar, Y. Ozyazgan, S. N. Esatoglu, E. Cerme, V. Hamuryudan, M. Melikoglu, I. Fresko, S. Yurdakul, H. Yazici, G. Hatemi

Publikováno v: Annals of the Rheumatic Diseases. 81:1760-1760

BackgroundExperience with mycophenolate in uveitis associated with Behçet’s syndrome (BS) is limited.ObjectivesWe aimed to report the efficacy and safety of mycophenolate mofetil (MMF) and mycophenolate sodium (MPA) in the treatment of BS uveitis.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::64d13332494e46e4a48b212e82c7e170
https://doi.org/10.1136/annrheumdis-2022-eular.3880

Zobrazit plný text záznamu

AB0601 FACTORS ASSOCIATED WITH THROMBOSIS IN BEHÇET SYNDROME: A SYSTEMATIC REVIEW AND META-ANALYSIS

Autor: G. Guzelant Ozkose, B. Yurttas, M. C. Ar, S. N. Esatoglu, V. Hamuryudan, H. Yazici, G. Hatemi

Publikováno v: Annals of the Rheumatic Diseases. 81:1427.1-1427

BackgroundBehçet syndrome (BS) is a unique vasculitis that can affect arteries and veins of all sizes. Thrombosis is an important component of vascular involvement in BS. Although several studies were conducted to highlight the mechanism of thromboi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d53218590d8de1f46afebc426e0a375d
https://doi.org/10.1136/annrheumdis-2022-eular.3897

Zobrazit plný text záznamu

AB0635 Central Nervous System Involvement and Mimickers in ANCA Associated Vasculitis

Autor: Y. Yagiz Ozogul, S. N. Esatoglu, M. Ozogul, O. Kizilkilic, Y. Ozguler, V. Hamuryudan, G. Hatemi

Publikováno v: Annals of the Rheumatic Diseases. 81:1444.2-1445

BackgroundCentral nervous system (CNS) involvement is rare in ANCA associated vasculitis (AAV). Besides, complications of immunosuppressive (IS) therapy or other conditions that mimic CNS involvement may occur in some AAV patients.ObjectivesWe aimed

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::46149688cc044bc5ead15165543b032b
https://doi.org/10.1136/annrheumdis-2022-eular.4011

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání